You are here: Industry Insights > Daewoong Pharmaceutical

News List

Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment prnasia
September 30, 2020
Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon) announced the result of its phase 2 clinical trial on enavogliflozin, SGLT2 inhibitor for diabetes currently in the process of development, for the first time at the ...
Daewoong finds niclosamide effective against Covid-19 in animal tests pharmaceutical-technology
June 11, 2020
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
Daewoong Pharmaceutical introduced the excellence of NABOTA® (Prabotulinumtoxin A) biospectrumasia
July 09, 2019
Botulinum toxin drug product manufactured by Daewoong proved efficacy and safety through FDA approval based on its non-inferiority results to Botox and stability in large-scale global clinical trials
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate pharmafocusasia
December 19, 2018
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with ....